

Alaska Vaccine-Preventable Disease Surveillance Report

4th Quarter 2019 (October-December)

The purpose of this report is to provide timely vaccine-preventable disease information to health care providers and other stakeholders for situational awareness.

Summary of Reported Cases of Select Vaccine-Preventable Disease, Alaska

Disease	2019*†								2018*†	
	Q4 (Oct-Dec)							Q4 Total	YTD	Annual Total
	Anch	Mat-Su	Gulf Coast	Interior	Northern	Southeast	Southwest			
<i>Haemophilus influenzae</i> , invasive disease	4	1	0	1	1	1	0	8	34	37
Hepatitis A	0	0	0	0	0	0	0	0	2	1
Hepatitis B, acute	1	0	0	0	0	0	0	1	6	7
Measles	0	0	0	0	0	0	0	0	1	0
Meningococcal invasive disease	0	0	0	0	0	0	0	0	2	3
Mumps	0	0	0	0	0	0	0	0	1	225
Pertussis	4	1	0	2	6	0	0	13	42	91
Pneumococcal invasive disease	25	5	5	7	2	2	1	47	176	141
Tetanus	0	0	0	0	0	0	0	0	1	0
Varicella	0	3	1	1	0	1	0	6	22	34

*Counts are provisional and may be updated.

†Includes confirmed and probable cases.

Haemophilus influenzae, invasive disease

During the October-December 2019 period, 8 cases were reported to the Alaska Section of Epidemiology (SOE):

- All the cases were confirmed by culture
- Isolate serotypes: 2 Hib, 1 Hif, and 5 non-typeable
 - 2/3 (67%) isolates serotyped from cases involving children <5 years of age, were vaccine-preventable

Age Group (years)	No. Cases	No. Hib Cases, Hib Vax Up-to-Date (UTD)±
<2	3 (37%)	3 (100%)
2-4	0	0
≥5	5 (63%)	N/A

Hepatitis B, acute

During the October-December 2019 period, 1 case was reported to the SOE:

- The case had signs and symptoms of acute viral hepatitis and was confirmed by serology; HBsAg-positive and IgM HBcAb-positive

Age Group (years)	No. Cases	No. Cases Hep B Vax UTD±
<15	0	0
15-19	0	0
20-29	0	0
30-39	0	0
40-49	1 (100%)	0
50-59	0	0
≥60	0	0

Pertussis

During the October-December 2019 period, 13 cases were reported to the SOE:

- 8 cases were confirmed by PCR and 3 were epi-linked to laboratory-confirmed cases
- An outbreak of pertussis occurred in the Northern region during this time period but it appears to have concluded in early December.

Age Group (years)	No. Cases	No. Cases DTaP/Tdap Vax UTD±
<1 year	3 (23%)	3 (100%)
1-6 years	0	0
7-10 years	1 (8%)	1 (100%)
11-19 years	6 (46%)	5 (83%)
≥20 years	3 (23%)	1 (33%)



Pneumococcal invasive disease (IPD)

During the October-December 2019 period, 47 cases were reported to the SOE:

- All the cases were confirmed by either PCR or culture isolation of *Streptococcus pneumoniae* from a normally sterile body site
- 46 cases had isolates submitted to the Arctic Investigations Program for serotyping
 - 40/46 (87%) isolates serotyped from cases involving persons ≥ 65 years of age, were vaccine-preventable

Age Group (years)	No. Cases	No. Cases PCV13 Vax UTD	No. Cases PPSV23 Vax UTD [‡]
<2	0	0	N/A
2-4	0	0	N/A
5-64	42 (89%)	N/A	N/A
Non-Native 50-64	9	N/A	N/A
Alaska Native 50-64	10	N/A	6 (60%)
≥ 65	5 (11%)	2 (40%)	1 (20%)

Varicella

During the October-December 2019 period, 6 cases were reported to the SOE:

- None were confirmed by viral culture or PCR
- 2 cases were epi-linked to laboratory-confirmed case
- No outbreaks were reported

Age Group (years)	No. Cases	No. Cases VAR Vax UTD [‡]
< 1	1 (17%)	N/A
1-6	4 (67%)	2 (50%)
7-10	0	0
11-19	0	0
≥ 20	1 (16%)	0

[‡]Based upon the Advisory Committee on Immunization Practice's routine age-appropriate immunization recommendations for children and adults who are not at increased risk for this disease.

VPD Updates and Reminders

- **Measles:** For the latest surveillance data from CDC visit: <http://www.cdc.gov/measles/cases-outbreaks.html>
- **Mumps:** For the latest surveillance data from CDC visit: <http://www.cdc.gov/mumps/outbreaks.html>
- **Varicella:** Providers should attempt to obtain a specimen for laboratory confirmation on any patient with suspected varicella, as the result can provide assurance in the clinical setting and impact public health decisions. For more information visit: <http://dhss.alaska.gov/dph/Epi/id/SiteAssets/Pages/Varicella/Information%20for%20HealthCare%20Providers%202016.pdf>
- Conditions reportable to public health in Alaska, available at: <http://dhss.alaska.gov/dph/Epi/Pages/pubs/conditions/default.aspx>
- Recommended immunizations for children and adults, and administration schedules: <http://dhss.alaska.gov/dph/Epi/iz/Pages/parents.aspx>
- Cases are defined according to national standards: <https://www.cdc.gov/nndss/case-definitions.html>

VPD Surveillance Coordinator Contact: Stephanie Massay, Phone 907-269-8011, Email stephanie.massay@alaska.gov

